iX Biopharma (SGX:42C) Long-Term Debt : S$1.80 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Long-Term Debt?

iX Biopharma's Long-Term Debt for the quarter that ended in Dec. 2024 was S$1.80 Mil.

iX Biopharma's quarterly Long-Term Debt declined from Dec. 2023 (S$2.62 Mil) to Jun. 2024 (S$2.18 Mil) and declined from Jun. 2024 (S$2.18 Mil) to Dec. 2024 (S$1.80 Mil).

iX Biopharma's annual Long-Term Debt declined from Jun. 2022 (S$0.88 Mil) to Jun. 2023 (S$0.57 Mil) but then increased from Jun. 2023 (S$0.57 Mil) to Jun. 2024 (S$2.18 Mil).

iX Biopharma Long-Term Debt Historical Data

The historical data trend for iX Biopharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Long-Term Debt Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Long-Term Debt

Get a 7-Day Free Trial

3.44

3.20

0.88

0.57

2.18

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															0.70	0.57	2.62	2.18	1.80

iX Biopharma (SGX:42C) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

iX Biopharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines